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Clinical, electrophysiologicand follow-updata were ana-
lyzed for 108 patients with aborted sudden death. The
mean follow-upinterval was 2 years. All patients under-
went baseline drug-free invasive electrophysiologicstud-
ies. Seventy-five patients (group [) had inducible ven-
tricular arrhythmias (including nonsustained and
sustained ventricular tachycardia and ventricular fi-
brillation) and 33 patients (group II) had no inducible
arrhythmias. Noninducibility was not predictive of a fa-
vorable outcome, because the incidence of both sudden
death and recurrent ventricular tachycardia was similar
in the two groups.
Treatment guided by electrophysiologic testing was
used in 17 patients; in 13 (17%) in group [arrhythmias
became noninducible, and in 4 (5%) sustained ventric-
ular arrhythmias became nonsustained after adminis-
tration of conventional drugs. There was a significantly
higher incidence of sudden death and recurrent ven-
tricular tachycardia in the 4. patients with inducible ar-
Prior studies (1,2) have shown that empiric therapy of out-
of-hospital survivors of cardiac arrest unrelated to a trans-
mural myocardial infarction is associated with a 30% in-
cidence rate of recurrent cardiac arrest during the first year
and an up to 45% recurrence rate of sudden death at 2 years .
These disappointing results have prompted investigators to
look for more effective treatment modalities. Ruskin et al.
(3) and Josephson et al. (4) were the first to apply electro-
pharmacologic testing for the management of survivors of
sudden death. These and several subsequent studies (5-9)
suggested that long-term antiarrh ythmic therapy that sup-
pressed inducible ventricular arrhythmias was generally as-
sociated with excellent short- and long-term survival. On
the other hand , patient s who were discharged on therapy
that did not suppress inducible ventricular arrhythmias had
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rhythmias (n = 3, 75%) compared with the 13 patients
whose arrhythmias were noninducible (n = 2, 15%) (p
< 0.05). For the group as a whole, 11% died suddenly
and 15% had recurrence ofventricular tachycardia. Sixty-
four patients were treated with amiodarone and, of these,
four (6%) died suddenly during the follow-upperiod and
nine (14%) had recurrent ventricular tachycardia.
Ventricular arrhythmias could be induced in 69% of
patients with aborted sudden death but inducibility could
be suppressed in only 20% of them. The role of therapy
guided by electrophysiologic testing could therefore not
be fully assessed. The findings reveal a significant re-
currence rate of symptomatic, potentially life-threat-
ening ventricular arrhythmias in medically treated pa-
tients with aborted sudden death. The information
discussed in this report may serve as a standard by which
to measure the efficacy of new therapeutic modalities.
(J Am Coli Cardiol 1987;10:291-8)
a significantly worse prognosis (3,6 ,7 ,9). In addition, base-
line noninducibility during e1ectrophysiologic testing was
generally considered to be a good prognostic sign (3,5,6,8,9).
However, the latter finding has not been universally con-
firmed. For example , in one of the largest studies to date
( 10), there was a similar incidence of sudden death for
patients with inducible ventricular arrhythmias compared
with those with nonindu cible arrhythmia. Most of the early
studies (3-8) suffer from several shortcomings including
relatively small sample sizes , short follow-up periods or use
of stimulation protocols , or all three , that by present stan-
dards would beconsidered inadequ ate . Last, in none of these
studies was the recurrence rate of nonlethal sustained ven-
tricular arrhythmias reported .
The importance of discern ing the efficacy of current med-
ical therapy for patients with aborted sudden death is high-
lighted by the development or refinement of newer treatment
modalitie s; namely, surgical resection of the arrhythmogenic
foci (II), catheter ablation of the ventricular tachycardia
foci (12) and use of the autom atic internal cardioverter-
defibrillator (13). The efficacy of these or any new treat -
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ments must be compared with results of current medical
practice. We therefore examined our experience with 108
survivors of sudden cardiac death whose therapy was de-
termined by electropharmacologic testing. Clinical, electro-
physiologic and therapy data were assessed for their relation
to recurrent sudden death or sustained symptomatic non-
lethal ventricular tachycardia, or both, during long-term
follow-up.
Methods
Study patients. Between June 1979 and April 1985,
238 consecutive patients were admitted to the University of
California, San Francisco Medical Center after surviving
one or more episodes of cardiac arrest. Only patients who
had undergone baseline electrophysiologic ventricular
tachycardia induction studies after admission were included
in the present study. Excluded from study were 63 patients
who either were treated with empiric drug therapy (20 pa-
tients) or had undergone antiarrhythmic or surgical therapy
at the time of electrophysiologic study (43 patients). Also
excluded were patients whose cardiac arrest occurred in the
setting of an acute myocardial infarction «48 hours) (50
patients), idiopathic long QT syndrome (6 patients), coro-
nary artery spasm (6 patients) and the Wolff-Parkinson-
White syndrome (5 patients). Thus 108 of the 238 patients
were included in this study.
Of the 108 patients selected for analysis, 73 were men
(68%) and 35 were women (32%). The mean age of the
sample was 59 ± 14 years (± SD) (range 7 to 86). The
earliest spontaneous rhythm recorded at the time of cardiac
arrest was ventricular fibrillation in 84 patients (78%), ven-
tricular tachycardia in 17 (16%) and asystole in 2 (2%). In
five patients (5%), the rhythm was not documented before
cardioversion.
Study protocol. Electrophysiologic studies were per-
formed 5 days to 6 weeks after the episode of cardiac arrest.
After informed consent was obtained, all antiarrhythmic
medications were discontinued for at least four half-lives.
Studies were performed in the fasting, unsedated state. Two
quadripolar electrode catheters were inserted percutaneously
into a femoral vein; one was positioned across the tricuspid
valve for recording the His bundle electrogram, and the
other was initially positioned against the high lateral right
atrium. In patients undergoing left ventricular stimulation,
a bipolar electrode catheter was inserted percutaneously into
a femoral artery and positioned against the apex of the left
ventricle. Electrocardiographic (ECG) leads VI, I and III
and intracardiac electrograms were recorded using a VR-12
Electronics for Medicine recorder. Standard atrial overdrive
or premature stimulation was used to study sinus node func-
tion, atrioventricular (AV) conduction or inducible supra-
ventricular arrhythmias. The high right atrial catheter was
then positioned against the apex of the right ventricle. Ven-
tricular stimulation was performed with 2 ms pulses, deliv-
ered by a programmable stimulator (Bloom) at a constant
current of 5 rnA. Right ventricular drive was instituted at
the right ventricular apex at a cycle length of 500 ms and
diastole was scanned with one, two, and then three extra-
stimuli as described in a previous report (6). Short bursts of
right ventricular overdrive pacing were then performed at
cycle lengths of 600 to 300 ms. If ventricular tachycardia
was not induced with right ventricular stimulation, left ven-
tricular stimulation was performed (except in patients stud-
ied before September 1981 or in whom left ventricular cath-
eterization was not technically feasible). In patients who
did not have ischemic heart disease and whose arrhythmia
was not induced with this protocol, ventricular stimulation
was repeated during continuous infusion of I to 5 JLg/min
of isoproterenol, titrated to maintain a heart rate of 110 to
120 beats/min.
Since September 1981, two changes have been made in
the protocol: I) if sustained arrhythmia was not induced by
right ventricular apical stimulation, the stimulation protocol
was repeated at the right ventricular outflow tract; and 2)
left ventricular stimulation was employed only if the ar-
rhythmia was not inducible from two sites in the right ven-
tricle. Sustained ventricular tachycardia was defined as ven-
tricular tachycardia lasting >30 seconds or requiring direct
current cardioversion or overdrive pacing for termination.
Nonsustained ventricular tachycardia was defined as ven-
tricular tachycardia of six beats to 30 seconds in duration.
Noninducibility was defined as the occurrence of five or
fewer nondriven ventricular repetitive complexes.
Electropharmacologic testing. Patients were initially
tested with intravenous procainamide unless there was a
prior history of drug toxicity or inefficacy. If tachycardia
was noninducible, the patients were treated with oral pro-
cainamide at a dose that replicated the blood procainamide
level found in the laboratory. Other conventional drugs or
experimental agents were similarly chosen on the basis of
a history of drug intolerance or inefficacy, presence or ab-
sence of heart failure or inducibility or noninducibility of
the arrhythmia during exercise. For this study, standard
agents included quinidine, procainamide, disopyramide, lid-
ocaine, phenytoin or verapamil. Experimental agents in-
cluded amiodarone, mexiletine, propafenone, encainide, so-
talol and flecainide. Several of the drugs classified as
experimental during the study period have now been ap-
proved.
The following intravenous drug doses were usedfor test-
ing: procainamide, 10 to 15 mg/kg (50 mg/min); propran-
olol, 0.2 mg/kg (l mg/min); lidocaine, bolus infusion of
225 mg over 20 minutes, followed by a 2 mg/min continuous
infusion; propafenone, bolus infusion of 2 mg/kg, followed
by a 1 to 2 mg/min continuous infusion; and amiodarone,
5 mg/kg over 30 min. The following doses of oral agents
were tested at trough blood levels after administration of a
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by the Mantel-Cox statistic. The relative importance of clin-
ical variables in predicting survival were assessed with a
stepwise Cox regression analysis.
*A maximum or two extrastimuli were used because of induction of
rapid polymorphous ventricular tachycardia. LV =' left ventricular; NSVT
= non sustained ventricular tachycardia; RV = right ventricular: Sus VT
= sustained ventricular tachycardia; VF = ventricular fibrillation.
Results
Relation of the clinical to induced arrhythmia. Of the
84 patients whose earliest recorded arrhythmia at the time
of cardiac arrest was ventricular fibrillation, arrhythmias
were noninducible at baseline study in 24 (29%) and were
inducible in 60 (71%) (20 had nonsustained ventricular
tachycardia, 31 had sustained ventricular tachycardia and 9
had ventricular fibrillation). Arrhythmia was non inducible
in 8 (47%) of 17 patients whose rhythm at the time of cardiac
arrest was ventricular tachycardia and inducible in 9 (53%)
(2 had nonsustained ventricular tachycardia, 5 had sustained
ventricular tachycardia and 2 had ventricular fibrillation).
Both patients whose initial rhythm was asystole had induc-
ible sustained ventricular tachycardia. Among the five pa-
tients whose cardiac arrest rhythm was not documented,
three had no inducible arrhythmias and two had sustained
ventricular tachycardia.
Baseline electrophysiologic study and drug testing.
Ventricular tachyarrhythmias were induced in 75 (69%) of
the 108 survivors of cardiac arrest. The induced arrhythmias
included nonsustained ventricular tachycardia in 23 patients,
sustained ventricular tachycardia in 41 patients and ven-
tricular fibrillation in II patients (see Table I for induction
protocol). Of the 75 tachyarrhythmias, 48 (64%) were in-
duced during right ventricular apical stimulation, 25 (33%)
during stimulation either at the right ventricular outflow tract
(12 patients) or left ventricular apex (13 patients) and 6
Table l. Baseline Electrophysiologic Induction Protocol
4
I
I
3
VF
(n = II)
I
3
I
6
3
17
9
I
Sus VT
(n = 41)
1*
2
I
3
4*
10
2
NSVT
(n = 23)
Noninducible
No. or Arrhythmia
Extrastimuli (n = 33)
RVapex
One
Two
Three 13
Isoproterenol 6
RVoutflow
One
Two
Three
LV apex
One
Two
Three H
Isoproterenol 6
sufficient number of doses to attain a steady state serum
drug level: procairiarnide, 3 to 8 g/day; quinidine, 1.2 to
1.6 g/day; disopyramide, 400 to 600 mg/day; propranolol,
160 to 480 mg/day; tocainide, 0.8 to 1.2 g/day; nadolol ,
240 to 300 mg/day; mexiletine, 300 to 600 mg/day; en-
cainide, 140 to 200 mg/day.
Electropharmacologic testing was usually continued un-
til ventricular tachycardia could no longer he induced bv
hoth right and left ventricular stimulation, even when ven-
tricular tachycardia had been induced by right ventricular
stimulation in the baseline study. II' intravenous procain-
amide proved unsuccessful in suppressing ventricular tachy-
cardia inducibility, quinidine or disopyramide was generally
not tested. When the induction of ventricular tachycardia
could not be suppressed by one or more of the conventional
drugs, treatment with experimental agents was initiated. For
most, this consisted of amiodarone, SOO mg/day orally.
Patients treated with amiodarone did not undergo repeat
studies (14).
In addition to pharmacologic therapy, six patients under-
went a surgical procedure for control of their arrhythmias.
These included coronary artery bypass grafting in two pa-
tients, coronary artery bypass grafting with aneurysmectomy
in one, implantation of an automatic implantable defibril-
lator in two and coronary angioplasty in one.
Chronic drug therapy and follow-up. Patients were
followed up on a regular basis by either one of the inves-
tigators or the patient's referring physician. Conventional
drug therapy was adjusted to yield serum levels matching
levels found to be successful in suppressing ventricular
tachycardia induction in the laboratory. If drug toxicity oc-
curred in the course of long-term therapy, but efficacy was
still demonstrable, repeat invasive testing was performed
using a drug from the same antiarrhythmic drug category
(15). In patients treated with amiodarone, the dose was
tapered to 600 rng/day after 6 weeks of therapy and to 400
rug/day after 3 months; subsequent adjustments in the dose
depended on the clinical response and development of ad-
verse effects.
Twenty-four hour ambulatory ECG recordings were ob-
tained every 3 to 6 months. Sudden death was defined as
unexpected natural death occurring during sleep or within
I hour of the patient's collapse. Recurrent ventricular tachy-
cardia was defined as a sustained, symptomatic arrhythmia
that was electrocardiographically documented.
Statistical analysis. Descriptive and inferential statistics
were used to analyze the data. Comparisons between groups
with respect to arrhythmia inducibility were carried out us-
ing chi-square analysis and Fisher's exact test for nominal
data and analysis of variance for interval data. Life-table
survival curves utilizing total cardiovascular deaths, sudden
cardiac deaths and recurrences of sustained ventricular
tachycardia were constructed from the date of the cardiac
arrest. Differences between survival curves were assessed
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NI = noninducible: other abbreviations as in Table I.
Table 2. Results of Electropharmacologic Testing (group 1,
75 patients)
(8%) during programmed stimulation and concomitant iso-
proterenol infusion. The mean cycle length of induced non-
sustained ventricular tachycardia was 221 ± 31 versus 274
± 67 ms for sustained ventricular tachycardia (p < 0.001).
Unimorphic ventricular tachycardia was induced in 85% of
the patients with sustained versus 57% of those with non-
sustained ventricular tachycardia (p < 0.01). Termination
of nonsustained ventricular tachycardia was spontaneous in
23, with the longest episode lasting 15 seconds. Termination
of sustained ventricular tachycardia or ventricular fibrillation
was accomplished by overdrive pacing in 18 patients and
by direct current cardioversion in 34. No ventricular ar-
rhythmia (fewer than five repetitive complexes) could be
induced by programmed stimulation or isoproterenol admin-
istration, or both, in 33 patients.
After the baseline study, patients with inducible arrhyth-
mias underwent drug testing with one or more conventional
or experimental drugs (Table 2). The most commonly used
antiarrhythmic agent was intravenous procainarnide (53 trials).
Comparison of baseline arrhythmia induction and the results
after drug testing are detailed in Table 2.
Comparison of inducible and noninducible groups.
We found no significant differences in either treatment mo-
dality (conventional versus experimental drugs) or outcome
among the three subgroups of patients with inducible ven-
tricular arrhythmias (sustained ventricular tachycardia in 41 ,
nonsustained ventricular tachycardia in 23 and ventricular
fibrillation in II patients) and, therefore, patients with in-
ducible ventricular tachyarrhythmias were treated as a single
cohort (group I, n =: 75) and contrasted with those without
inducible arrhythmias (group II, n =: 33). The clinical char-
acteristics of these two patient groups are detailed in Table
Baseline Induced Rhythm
Procainamide (n = 53)
NSVT
Sus VT
VF
Quinidine (n = 9)
NSVT
Sus VT
Beta-blockers (n = 9)
NSVT
Sus VT
VF
Other conventional drugs (n = 7)
NSVT
Sus VT
Experimental drugs (n = 7)
NSVT
Sus VT
After Drug Testing
NI NSVT Sus VT VF
4
4 7 28
2 7
3
2 4
3 2
3
3
3
2
3. Seventy-three percent of the patients in group I had coro-
nary artery disease versus 33% in group II (p < 0.005).
However, the severity of documented coronary artery dis-
ease (270% stenosis) was not significantly different for the
two groups. Patients with inducible arrhythmias (group I)
also had a higher incidence of prior myocardial infarction
and ventricular aneurysm, as well as a lower ejection frac-
tion than group II patients. Group II patients (noninducible
arrhythmia), on the other hand, were more likely than group
I patients to have no known heart disease.
Group I: Patients With Inducible Arrhythmias
Treatment (Fig. 1). Group I comprised 75 patients. Of
these, five subsequently underwent a surgical intervention
including coronary bypass surgery (three patients), angio-
plasty (one patient) and insertion of an automatic internal
defibrillator (one patient) before hospital discharge. Long-
term oral conventional antiarrhythmic therapy (including
procainamide or quinidine) was prescribed for 17 patients
(23%). Among these, conventional therapy had prevented
the induction of ventricular tachyarrhythmias in 13 (Table
2), whereas 4 patients with sustained ventricular tachycardia
or ventricular fibrillation had nonsustained ventricular
tachycardia after drug testing. Fifty-six patients who, de-
spite serial drug testing, continued to have inducible tach-
yarrhythmias were discharged on either amiodarone (52 pa-
tients) or an experimental antiarrhythmic drug (two patients
receiving propafenone, one receiving mexiletine and one
receiving encainide). Two patients, both of whom had in-
ducible polymorphic nonsustained ventricular tachycardia
and whose cardiac arrest was believed due to an acute isch-
emic event, were discharged with no antiarrhythmic ther-
apy.
Follow-up. Group I patients have been followed up for
an average of 26 ± 20 months (range 1 to 84). There have
been 17 cardiac deaths (23%), 8 (II %) of which were sud-
den, and two noncardiac deaths. Nonarrhythmic cardiac
death was due to congestive heart failure in seven patients
and myocardial infarction in two. The noncardiac deaths
were due to a cerebral vascular accident in one and cirrhosis
of the liver in the other. In addition, 11 patients (15%) had
recurrence of symptomatic ventricular tachycardia.
Among the 13 patients who were discharged on conven-
tional therapy that prevented ventricular tachycardia induc-
tion, I died suddenly at 17 months after an episode of chest
pain and I had recurrent sustained ventricular tachycardia
within a month of hospital discharge. This latter patient
subsequently underwent three vessel coronary bypass graft-
ing and is alive without recurrence of ventricular tachycardia
after 51 months of follow-up. Only four patients who showed
incomplete arrhythmia suppression were fol1owed up with
long-term conventional oral therapy. One of the four died
suddenly and two had recurrences of sustained ventricular
ixcc Vol. 10. No.2
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Category
Age (mean ± SO) (yr)
Sex
Male
Female
Coronary artery disease
One and two vessel
Three or more vessel
Previous MI
Ventricular aneurysm
Cardiomyopathy
Ejection fraction
Bundle branch block
Other heart disease
Hypertension
Mitral valve prolapse
Valvular heart disease
Other
None known
Therapy
No antiarrhythmic agents
Conventional
Amiodarone
Other experimental
Surgery/AICD
Recurrent VT
Deaths (total)
Cardiac, nonsudden
Cardiac, sudden
Noncardiac
Follow-up (rno)
Inducible Noninducible
Arrhythmia Arrhythmia
(n = 75) (n = 33)
57 ± 13 59 ± 12
55 (73) 18 (55)
20 (27) 15 (45)
55 (73) II (33)
25 (45) 4 (16)
16 (29) 3 (10)
46 (61) 7 (21)
II (15) I (3)
25 (33) II (38)
42 ± 15 53 ± 7
25 (3) 9 (27)
11 (15) II (33)
6 (8) 4 (12)
4 (5) 3 (10)
3 (4) I (3)
5 (7) 11m)
2 (I) 7 (21)
16 (21) 12 (36)
52 (69) 13 (39)
5(7) I (3)
5(7) I (3)
11 (15) 5 (15)
20 (27) 8 (24)
9 (45) 3 (375)
8 (40) 3 (375)
3 (15) 2 (25)
26 ± 20 27 ± 19
p Value
<0.05
«l.05
<0.001
<O.OOt
<0.05
<0.0001
<0.05
<0.001
<0.01
Numbers in parentheses are percentages. AICD = automatic internal cardioverter-defibnllator; MI = myocardial infarction; other abbreviations as
in Table I.
tachycardia, The sudden death occurred within 1 month of
hospital discharge. The two recurrences of sustained ven-
tricular tachycardia occurred at 1 and 9 months, respec-
tively. One patient underwent automatic internal cardio-
verter-defibrillator implantation and the other responded to
higher doses of quinidine. Both are alive after an average
of 28 ± 5 months of follow-up.
Six sudden deaths (JJ%) occurred among the 58 patients
whose tachyarrhythmia was still inducible during testing.
Four of these sudden deaths occurred within 4 months of
initiating amiodarone therapy. The two other sudden deaths
occurred in patients in whom amiodarone either alone or in
combination with a class IA drug had failed to prevent an
average of four recurrences of sustained ventricular tachy-
cardia during an average of 16 ± 5 months of follow-up.
At the time of these deaths, one patient was receiving no
antiarrhythmic medication after automatic internal cardio-
verter-defibrillator implantation and the other was receiving
sotalol.
Recurrent nonlethal sustained ventricular tachycardia or
ventricular fibrillation occurred in 8 (/2%) of these 58 pa-
tients; of these, 6 were taking amiodarone and 2 were taking
other experimental drugs. Four patients treated with amio-
darone had one or more recurrences within 6 months of
therapy initiation. Sustained ventricular tachycardia devel-
oped I month after initiation of propafenone in one patient
who was then successfully treated with amiodarone for 28
months. Severe tremors necessitated withdrawal of amio-
darone and the patient was treated with a series of drug
combinations during which he experienced> 10 recurrences
of symptomatic sustained ventricular tachycardia. The ar-
rhythmia is currently controlled with flecainide. One patient
who was withdrawn from amiodarone because of lung tox-
icity experienced recurrent aborted sudden death while tak-
ing bepridil and underwent insertion of an automatic defi-
brillator. The latter two patients are alive after an average
follow-up of 57 ± 4 months.
Thus, there was a significant difference in the recurrence
rates of sudden death and nonlethal sustained ventricular
tachycardia between patients whose arrhythmia was sup-
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CONVENTIONAL
DRUG THERAPY
17
P < 0.05
NO DRUGS
13
CONVENTIONAL THERAPY
7
Figure 1. Flow diagram summarizing therapy
and follow-up. Amio = amiodarone; partial
control = inductionof nonsustained ventricular
tachycardia in those with baseline induciblesus-
tained ventricular tachycardia or fibrillation; SeD
= sudden cardiac death; VT = recurrent ven-
tricular tachycardia.
pressed by conventional therapy during electropharmacol-
ogic test ing and those whose arrhythmia was not totally
suppressed (p < 0.05). However, the overall frequency of
recurrence of ventricular tachycardia or sudden death, or
both, among those treated with conventional drugs and those
receiving amiodarone or other experimental drugs, or both,
was not different (29 versus 26%, respectively).
Group l/: Patients With Nonindu cible Arrhythmias
Treatment. Thirty-three patients had no inducible ven-
tricular arrhythmia at baseline study. Thirteen of these (39%)
were discharged without antiarrhythmic therapy: six (46%)
had aborted sudden death after initiation of a type I anti-
arrhythmic drug , five (39%) had documented coronary ar-
tery disease and were treated with medical or surgical ther-
apy and two (15%) had no structural heart disease . Among
these 13, I patient died suddenly (previous sudden death
while taking class I drugs) and I had recurrent ventricular
tachycardia that is currently controlled with quinidine ther-
apy. Twelve patients were treated with amiodarone and no
sudden deaths have occurred among these patients. How-
ever, 3 (25%) of the 12 have had one or more recurrences
of ventricular tachycardia: I patient at I month, I at 4 and
10 months and I at 27 months of therapy. These patients
are currently controlled with addition of procainamide (one
patient) or with an increased dose of amiodarone (two pa-
tients) . Seven of the patients with a noninducible arrhythmia
were treated with type I agent s on an empiric basis. On
follow-up, one patient died suddenly and one had recurrence
of ventricular tachycardia. One patient who was treated with
encainide died suddenly 14 months after initiating drug ther-
apy .
Follow-up. After a mean follow -up of 27 ± 19 months
for the non inducible group, 7 (21%) of the 33 patients died .
Three (9% ) died suddenly, two of congestive heart failure
and two of noncardiac cau ses . Five (15%) suffered from
recurrent ventricular tachycardia . Six (30% ) of the 20 treated
with antiarrhythmic drug s either died suddenly or had re-
current ventricular tachycardia . Two ( 15%) of 13 patients
receiving no antiarrhythmic therapy either died suddenly or
had recurrent ventricular tachycardia . There was no stati s-
tical diffe rence in significant events between treated and
nontreated patients. Howe ver, none of the patients treated
with amiodarone died suddenly.
Life table and Cox regression analysis. Actuarial anal -
ysis of patient survival rates revealed a I year survival rate
of 87% and a 2 year survival rate of 83% for the entire
sample. The probabilities of I and 2 year survival for the
group II patients were 86 and 81% versus 87 and 84%,
lACC Vol. 10, No, 2
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respectively, for the group I patients (p = NS), The I and
2 year sudden death rates were also similar in both groups
(group I, 8.5 and 2% and group II, 7 and 6%, respectively)
as were the recurrence rates of sustained ventricular tachy-
cardia (group I, 12 and 2% versus group II, 7.5 and 13%).
Overall the highest probabilities for all cardiac deaths, sud-
den cardiac deaths and recurrence of sustained ventricular
tachycardia occurred in the first 6 months after the cardiac
arrest event (II, 8 and II %, respectively). The effect of
covariates on the occurrence of sudden cardiac death and
sustained recurrent ventricular tachycardia as determined by
a stepwise Cox regression revealed that none of the clinical
characteristics of the patients was predictive of sudden death
or recurrent ventricular tachycardia.
Discussion
Overall results. In the present study, our approach was
to assess drug efficacy for those with inducible ventricular
arrhythmias. If a drug could not be found to prevent the
induction of ventricular arrhythmias, then the patients were
usually treated with amiodarone. In the noninducible group,
effort was made to treat any possible etiologic cause (for
example, drug-induced arrhythmia or ischemia). Using this
approach, we found that 8% of the patients died suddenly
during the first year after cardiac arrest and II % had re-
current sudden death at 2 years. Our reported incidence of
sudden death is similar to that of previously reported series
using e1ectropharmacologic testing to guide therapy
(3,7,9,10,14). In addition, we found a substantial incidence
( 15%) of recurrent symptomatic ventricular tachycardia over
a 2 year period for these patients. The incidence of symp-
tomatic ventricular tachycardia in patients with aborted sud-
den death has received only scant appraisal in the medical
literature.
Patients with inducible ventricular arrhythmias. Our
results highlight the limitations of serial electropharmacol-
ogic testing in that drugs that rendered the arrhythmia non-
inducible were found in only approximately 20% of patients.
Conceivably, the incidence of finding an effective drug might
have been higher if more drugs or drug combinations had
been tried. Most patients were tested with only one class
IA drug and if arrhythmias were subsequently found in-
ducible these patients were treated with amiodarone. In the
group with inducible arrhythmia, only 17 patients were con-
tinued on long-term oral conventional therapy. Thirteen pa-
tients were given long-term treatment with a type I drug
that suppressed arrhythmia induction, and four patients were
given treatment with drugs that changed sustained ventric-
ular arrhythmias to nonsustained arrhythmias. The relatively
small number of patients given long-term treatment on the
basis of serial electrophysiologic testing limits any conclu-
sions with respect to the efficacy of this approach. We did,
however, find a statistically significant increase in the in-
cidence of sudden death and recurrent ventricular tachy-
cardia in those whose arrhythmia remained inducible. Whereas
the efficacy of electropharmacologic testing supports the
observations of many other workers (3-9), our observations
have bearing on the appropriate end point used for such
testing. The efficacy of partial arrhythmia modification by
drugs (that is, conversion to a slower ventricular tachycardia
rate or induction of a nonsustained arrhythmia) is still de-
batable (16). Our observations suggest that conversion of a
sustained arrhythmia to a nonsustained arrhythmia (mini-
mum of >6 to 15 beats in our series) is an inappropriate
therapeutic end point.
Patients with noninducible arrhythmias. We were un-
able to use serial testing for the 33 patients who had no
inducible baseline ventricular arrhythmias. Limited conclu-
sions can be drawn from this group because treatment was
not homogeneous. Patients were treated either for pre-
sumptive drug-induced or ischemic-related arrhythmias or
with empiric drug therapy if no specific cause could be
discerned. We found no significant difference in the inci-
dence of sudden death or ventricular tachycardia between
the patient groups with inducible and noninducible arrhyth-
mia. In contrast to previous reports (5,6,8,9), we found that
baseline noninducibility did not predict a benign outcome.
However, our incidence of sudden death for the patients
with noninducible rhythm (3 of 33, 9%) was lower than that
reported by Roy et al. (15 of 67, 32%) (10). The different
incidence of sudden death may be related to either differ-
ences in the patient population or treatment regimens used.
Patients treated with amiodarone. Overall, a total of
64 patients were initially treated with amiodarone and 4
(6%) of these patients died suddenly. Of interest was the
finding that three of the four died suddenly within I month
after initiation of amiodarone, which may be related to in-
adequate loading to achieve full therapeutic effects. Nine
additional patients receiving amiodarone therapy had re-
current nonlethal ventricular tachycardia on follow-up eval-
uation. Twelve patients in whom amiodarone therapy was
discontinued because of toxic side effects were treated with
conventional or experimental drugs or underwent surgery
or insertion of an automatic internal defibrillator. Three
(25%) of these 12 died suddenly and 2 had nonfatal recurrent
ventricular tachycardia. No patients continuing amiodarone
have had a sudden death although the incidence of nonfatal
ventricular tachycardia or ventricular fibrillation is similar
to that of those who discontinued therapy. Our findings
confirm the previously reported efficacy of amiodarone ther-
apy for patients with aborted sudden death with inducible
arrhythmias after drug testing (6,17,18).
Clinical implications. Serial electropharmacologic test-
ing proved successful in only a minority of patients with
aborted sudden death. In addition, we found that use of
conversion of a sustained ventricular arrhythmia to a non-
sustained arrhythmia may be an inappropriate end point for
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serial testing. Overall, using such testing together with
amiodarone for those with persistent inducible arrhythmias,
we found that the overall incidence of sudden death over a
2 year follow-up interval was II %. This result compares
very favorably with prior studies (II ,19) in which empiric
drug or surgical therapy was utilized. Somewhat discour-
aging was the finding of a 15% incidence rate of recurrent
symptomatic ventricular tachycardia, suggesting that a size-
able cohort is still at risk for recurrent potentially malignant
arrhythmias. In addition, we found a high incidence of sud-
den death within 6 months after occurrence of aborted sud-
den death, suggesting the need for maximal early interven-
tion for these patients.
The incidence of sudden death in patients treated with
amiodarone was 6%, which again compared quite favorably
with prior studies of empiric treatment with conventional
drugs or coronary bypass surgery. Use of this drug is limited
by the substantial incidence of toxicity as well as by re-
currence of symptomatic ventricular arrhythmias. Seventy-
five percent of those who died suddenly while taking amio-
darone died within I month after initiation of therapy. This
finding suggests that either a longer hospital observation
period is required or that early combination drug therapy
may be necessary for these patients.
Our findings highlight the limitations of current medical
therapy for patients with aborted sudden death in that sub-
stantial numbers remain at risk for life-threatening cardiac
arrhythmias. This information serves as an important stan-
dard by which to measure the efficacy of newer therapeutic
modalities.
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